NIH Halts Drug Production

The National Institutes of Health’s Pharmaceutical Development Section temporarily suspends production following contamination issues.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The NIH Clinical Center in Bethesda, Maryland, where stoppage of drug production could affect some 46 clinical trialsWIKIMEDIA, CHRISTOPHER ZIEMNOWICZLast week (June 4), the National Institutes of Health (NIH) stopped production of drugs for 46 clinical trials, which were being manufactured at its Pharmaceutical Development Section, after Food and Drug Administration (FDA) inspectors last month discovered fungal contamination in two vials of albumin, The Wall Street Journal (WSJ) reported. According to the WSJ, vials from the same batch were used on six patients, none of which have shown signs of infection, the NIH said.

“Out of an abundance of caution, we’ve suspended use of all these products,” NIH’s Lawrence Tabak told Nature News.

In addition to the fungus, the WSJ reported that the FDA inspectors found “a range of manufacturing defects, from flaws in the air-handling system to insufficient employee training to overall lack of compliance with standard operating procedures.”

In an interview with the WSJ, NIH Director Francis Collins called the findings “distressing and unacceptable situation.”

“The fact that patients may have been put in harm’s way,” he added, “is deeply troubling.”

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Tracy Vence

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio